Targeting allergen to FcγRI

A strategy to treat allergic disease?

Kathryn E. Hulse, Judith A. Woodfolk

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Purpose of review: Targeting allergens to surface receptors on antigen presenting cells may provide a therapeutic strategy for allergic disease. This article discusses the immunomodulatory capacity of a molecule (H22-Fel d 1), which targets the major cat allergen, Fel d 1, to the high affinity IgG receptor, FcγRI, on human dendritic cells. Recent findings: The fusion protein, H22-Fel d 1, induced a semi-mature phenotype in dendritic cells characterized by production of inflammatory cytokines with no change in surface markers, suggesting tolerogenic capacity. At the T-cell level, H22-Fel d 1 stimulated increased proliferation coupled with amplification of T cells expressing IL-5 and IL-10. Further analysis revealed induction of diverse T cell subtypes characteristic of Th0, regulatory Th1 and regulatory Th2 cells. Notably, this effect was restricted to T cells isolated from cat-allergic patients. Despite the increase in IL-5-expressing T cells, responses induced by H22-Fel d 1 appeared to be regulated by IL-10. Comparison with nonreceptor-targeted allergens from cat and house dust mite confirmed that qualitative T-cell changes induced by H22-Fel d 1 were unique. Summary: H22-Fel d 1 induces a novel variation of the Th2 response, which incorporates elements of a protective T-cell response. Exploiting FcγRI-mediated pathways for allergen delivery may offer a new approach for treatment.

Original languageEnglish (US)
Pages (from-to)547-552
Number of pages6
JournalCurrent Opinion in Allergy and Clinical Immunology
Volume8
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Allergens
T-Lymphocytes
Cats
Interleukin-5
Interleukin-10
Dendritic Cells
Dermatophagoides Antigens
IgG Receptors
Th2 Cells
Antigen-Presenting Cells
Cytokines
Phenotype
Therapeutics
Proteins

Keywords

  • CD4+ T cells
  • Dendritic cell-based vaccines
  • Fcγ receptors
  • FcεRI
  • Fel d 1

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{84f368a577574df284e93add7d5577a6,
title = "Targeting allergen to FcγRI: A strategy to treat allergic disease?",
abstract = "Purpose of review: Targeting allergens to surface receptors on antigen presenting cells may provide a therapeutic strategy for allergic disease. This article discusses the immunomodulatory capacity of a molecule (H22-Fel d 1), which targets the major cat allergen, Fel d 1, to the high affinity IgG receptor, FcγRI, on human dendritic cells. Recent findings: The fusion protein, H22-Fel d 1, induced a semi-mature phenotype in dendritic cells characterized by production of inflammatory cytokines with no change in surface markers, suggesting tolerogenic capacity. At the T-cell level, H22-Fel d 1 stimulated increased proliferation coupled with amplification of T cells expressing IL-5 and IL-10. Further analysis revealed induction of diverse T cell subtypes characteristic of Th0, regulatory Th1 and regulatory Th2 cells. Notably, this effect was restricted to T cells isolated from cat-allergic patients. Despite the increase in IL-5-expressing T cells, responses induced by H22-Fel d 1 appeared to be regulated by IL-10. Comparison with nonreceptor-targeted allergens from cat and house dust mite confirmed that qualitative T-cell changes induced by H22-Fel d 1 were unique. Summary: H22-Fel d 1 induces a novel variation of the Th2 response, which incorporates elements of a protective T-cell response. Exploiting FcγRI-mediated pathways for allergen delivery may offer a new approach for treatment.",
keywords = "CD4+ T cells, Dendritic cell-based vaccines, Fcγ receptors, FcεRI, Fel d 1",
author = "Hulse, {Kathryn E.} and Woodfolk, {Judith A.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1097/ACI.0b013e32831665d2",
language = "English (US)",
volume = "8",
pages = "547--552",
journal = "Current Opinion in Allergy and Clinical Immunology",
issn = "1528-4050",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Targeting allergen to FcγRI : A strategy to treat allergic disease? / Hulse, Kathryn E.; Woodfolk, Judith A.

In: Current Opinion in Allergy and Clinical Immunology, Vol. 8, No. 6, 01.12.2008, p. 547-552.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Targeting allergen to FcγRI

T2 - A strategy to treat allergic disease?

AU - Hulse, Kathryn E.

AU - Woodfolk, Judith A.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Purpose of review: Targeting allergens to surface receptors on antigen presenting cells may provide a therapeutic strategy for allergic disease. This article discusses the immunomodulatory capacity of a molecule (H22-Fel d 1), which targets the major cat allergen, Fel d 1, to the high affinity IgG receptor, FcγRI, on human dendritic cells. Recent findings: The fusion protein, H22-Fel d 1, induced a semi-mature phenotype in dendritic cells characterized by production of inflammatory cytokines with no change in surface markers, suggesting tolerogenic capacity. At the T-cell level, H22-Fel d 1 stimulated increased proliferation coupled with amplification of T cells expressing IL-5 and IL-10. Further analysis revealed induction of diverse T cell subtypes characteristic of Th0, regulatory Th1 and regulatory Th2 cells. Notably, this effect was restricted to T cells isolated from cat-allergic patients. Despite the increase in IL-5-expressing T cells, responses induced by H22-Fel d 1 appeared to be regulated by IL-10. Comparison with nonreceptor-targeted allergens from cat and house dust mite confirmed that qualitative T-cell changes induced by H22-Fel d 1 were unique. Summary: H22-Fel d 1 induces a novel variation of the Th2 response, which incorporates elements of a protective T-cell response. Exploiting FcγRI-mediated pathways for allergen delivery may offer a new approach for treatment.

AB - Purpose of review: Targeting allergens to surface receptors on antigen presenting cells may provide a therapeutic strategy for allergic disease. This article discusses the immunomodulatory capacity of a molecule (H22-Fel d 1), which targets the major cat allergen, Fel d 1, to the high affinity IgG receptor, FcγRI, on human dendritic cells. Recent findings: The fusion protein, H22-Fel d 1, induced a semi-mature phenotype in dendritic cells characterized by production of inflammatory cytokines with no change in surface markers, suggesting tolerogenic capacity. At the T-cell level, H22-Fel d 1 stimulated increased proliferation coupled with amplification of T cells expressing IL-5 and IL-10. Further analysis revealed induction of diverse T cell subtypes characteristic of Th0, regulatory Th1 and regulatory Th2 cells. Notably, this effect was restricted to T cells isolated from cat-allergic patients. Despite the increase in IL-5-expressing T cells, responses induced by H22-Fel d 1 appeared to be regulated by IL-10. Comparison with nonreceptor-targeted allergens from cat and house dust mite confirmed that qualitative T-cell changes induced by H22-Fel d 1 were unique. Summary: H22-Fel d 1 induces a novel variation of the Th2 response, which incorporates elements of a protective T-cell response. Exploiting FcγRI-mediated pathways for allergen delivery may offer a new approach for treatment.

KW - CD4+ T cells

KW - Dendritic cell-based vaccines

KW - Fcγ receptors

KW - FcεRI

KW - Fel d 1

UR - http://www.scopus.com/inward/record.url?scp=56749105457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749105457&partnerID=8YFLogxK

U2 - 10.1097/ACI.0b013e32831665d2

DO - 10.1097/ACI.0b013e32831665d2

M3 - Review article

VL - 8

SP - 547

EP - 552

JO - Current Opinion in Allergy and Clinical Immunology

JF - Current Opinion in Allergy and Clinical Immunology

SN - 1528-4050

IS - 6

ER -